8SV1.F - WPD Pharmaceuticals Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.3650
-0.0015 (-0.41%)
At close: 4:12PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.3665
Open0.3700
Bid0.3730 x N/A
Ask0.3855 x N/A
Day's Range0.3530 - 0.3860
52 Week Range0.0030 - 1.7380
Volume44,000
Avg. Volume86,056
Market Cap12.237M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce that on May 21, 2020 Wake Forest University received a patent from the United States Patent and Trademark Office (“USPTO”) for a patent titled “EphA3 and Multi-Valent Targeting of Tumors” (under application number 15/958,608). The patent is exclusively licensed to WPD, and the patent relates to the WPD101 drug candidate, used in the therapy of glioblastoma multiform (“GBM”).

    • MarketWatch

      UPDATE: Moleculin Biotech, CNS Pharma shares remain halted on Nasdaq

      Moleculin Biotech Inc. and CNS Pharmaceuticals Inc. said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company. Shares werehalted temporarily on May 1 by the Securities and Exchange Commission in a halt that was meant to expire at 11.59 p.m. on May 15. The halt came because of questions regarding the accuracy of information in the marketplace about a drug candidate for the coronavirus illness COVID-19, the SEC said. Moleculin's stock was halted along with CNS and WPD Pharmaceuticals Inc. , because of questions relating to a drug candidate called WP1122. CNS was working with WPD to develop the drug; WPD had previously licensed rights to a portfolio of drug candidates including WP1122 from Moleculin Biotech for certain regions.

    • GlobeNewswire

      WPD Pharmaceuticals To Resume Trading

      VANCOUVER, British Columbia, May 15, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces that.

    • GlobeNewswire

      WPD Pharmaceuticals Comments on SEC Order

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, clarifies the temporary suspension on its trading ordered by the United States Securities and Exchange Commission (“SEC”). After trading hours on May 1, 2020 the SEC issued an Order (the “Order”) in the public interest and protection of investors requiring a suspension in the trading of securities of WPD Pharmaceuticals Inc. pursuant to Section 12(k) of the Securities Exchange Act of 1934.

    • SEC takes action against three more companies over COVID-19 claims
      MarketWatch

      SEC takes action against three more companies over COVID-19 claims

      The Securities and Exchange Commission temporarily halted trading in three more stocks on Monday because of questions regarding the accuracy of information in the marketplace about a drug candidate for the coronavirus illness COVID-19.

    • GlobeNewswire

      WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial

      The US Phase 2 trial Sponsor will be CNS and the Polish Phase 2 trial Sponsor will be WPD, a Polish corporation founded by Professor Waldemar Priebe, founder of both WPD and CNS. The Company expects to initiate both its Phase 2 US and Polish trial of Berubicin in adults with GBM during the second half of 2020.

    • CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
      PR Newswire

      CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial

      CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system in collaboration with WPD Pharmaceuticals Inc. (CSE:WBIO) (8SV1.F) ("WPD") a clinical stage pharmaceutical company, today announced it has identified several leading medical institutions in Poland to conduct its Berubicin Phase 2 clinical trial in adults with glioblastoma multiforme ("GBM"), an aggressive and incurable form of brain cancer.

    • GlobeNewswire

      WPD Pharmaceutical’s Annamycin Drug Approved for Accelerated European Clinical Trial

      VANCOUVER, British Columbia, April 29, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to.

    • GlobeNewswire

      WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin

      VANCOUVER, British Columbia, April 24, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to.

    • GlobeNewswire

      WPD Pharmaceuticals’ Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity

      WPD Pharmaceuticals Inc. (CSE:WBIO) (8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to provide an update on its Annamycin drug candidate. The phase 1 trial met its objective of demonstrating the safety of Annamycin.

    • GlobeNewswire

      WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences

      VANCOUVER, British Columbia, April 21, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company along with its.

    • GlobeNewswire

      WPD Pharmaceuticals’ License Partner, Moleculin Biotech to Host Conference Call to Discuss COVID-19 Potential in WP1122 Drug Candidate

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company announces that its license partner, Moleculin Biotech, Inc. (“Moleculin”) will be hosting a web-based investor conference call, today, April 16th at 4:30pm ET to explain the significance of the recent discovery that the active compound in WP1122 drug candidate has been shown to reduce replication of SARS-CoV-2 by 100%. WPD has licensed rights to a portfolio of drug candidates, including WP1122 through Moleculin.

    • CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals
      PR Newswire

      CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals

      CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that independent research by the University of Frankfurt found 2-deoxy-D-glucose ("2-DG") to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing.

    • GlobeNewswire

      WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company reports that the Company anticipates to resume trading at market open on Monday, April 13, 2020. WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules.

    • GlobeNewswire

      WPD Pharmaceuticals Clarifies News on Licensed Drug Candidate

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, at the request of IIROC, clarifies its press release released yesterday regarding the independent research on its WP1122 drug compound. In the prior press release, WPD disclosed that independent research found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing. WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech, Inc. (“Moleculin”)(MBRX) for use in 31 countries.

    • GlobeNewswire

      WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replication in Vitro by 100%

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that independent research on its WP1122 drug compound found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing. WPD in collaboration with its development partner CNS Pharmaceuticals, Inc. (“CNS”)(CNSP) intends to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2.

    • GlobeNewswire

      WPD Pharmaceuticals Provides Corporate Update

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to provide a corporate update on its business and the continued development of its portfolio of drug candidates. “We have made great strides advancing our comprehensive drug portfolio with our license partners, Moleculin Biotech and CNS Pharmaceuticals and we are looking forward to executing on our growth strategy.”

    • GlobeNewswire

      WPD Pharmaceuticals Welcome Dr. Waldemar Debinski to its Scientific Advisory Board

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is excited to announce that Dr. Waldemar Debinski, inventor of WPD101, WPD102 and WPD103 drug candidates has joined its Scientific Advisory Board. The Company’s name comes from the names of inventors Dr. Waldemar Priebe and Dr. Waldemar Debinski, which creates the “WPD” in WPD Pharmaceuticals.

    • GlobeNewswire

      WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces it has entered into a development agreement (the “Agreement”) with CNS Pharmaceuticals, Inc. (“CNS”)(CNSP) for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2. WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech, Inc. (“Moleculin”)(MBRX).

    • CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets
      PR Newswire

      CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets

      CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company primarily specializing in the development of novel treatments for cancers of the brain and central nervous system, announces it has entered into an agreement with WPD Pharmaceuticals Inc. (CSE: WBIO) for the development of several preclinical drug candidates including WP1122, which is being tested on a range of viruses including the coronavirus SARS-CoV-2. WPD Pharmaceuticals previously licensed rights to a portfolio of drug candidates, including WP1122, from Moleculin Biotech, Inc. for certain territories. WPD Pharmaceuticals was founded by Dr. Waldemar Priebe, the founder of the Company.

    • GlobeNewswire

      WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS

      VANCOUVER, British Columbia, March 19, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces, that.

    • GlobeNewswire

      WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that a patient from the Phase 1 clinical trial of its Berubicin drug for the treatment of glioblastoma multiforme ("GBM"), remains cancer free. The clinical trial was conducted by $4Bn pharmaceutical company, Reata Pharmaceuticals, Inc. GBM is an aggressive type of brain cancer and currently, there are no effective therapies approved to treat this disease.

    • GlobeNewswire

      WPD PHARMACEUTICALS RECEIVED $800,000 REIMBURSEMENT FROM $7.4 MILLION GOVERNMENT GRANT FOR DEVELOPMENT OF GLIOBLASTOMA DRUG

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that it has received from the Polish National Center for Research and Development (“NCRD”) approximately C$800,000 in reimbursement of costs for the development of WPD101. WPD101 is exclusively licensed from Wake Forest University. To date, WPD has received almost C$20 million in government grants for the development of its drug portfolio.

    • GlobeNewswire

      WPD Pharmaceuticals’ Brain Cancer Drug Received Positive FDA Pre-IND Guidance 

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to provide an update that through its license partner, CNS Pharmaceuticals, Inc. (“CNS”)(CNSP), it received positive feedback from the U.S. Food and Drug Administration (“FDA”) for its Pre-IND (Investigational New Drug) meeting proposal to use a lyophilized drug product, Berubicin, in Phase II clinical trials.

    • GlobeNewswire

      WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia

      WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”), a clinical stage pharmaceutical company is pleased to provide an update on the clinical drug studies of Annamycin in Acute Myeloid Leukemia (“AML”). WPD’s license partner Moleculin Biotech, Inc, (“Moleculin”) (MBRX) disclosed additional positive interim safety and efficacy data from one of the two ongoing open label, single arm Phase 1/2 studies of Annamycin for the treatment of relapsed or refractory AML.